PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups

BACKGROUND: Immunotherapy can become a crucial therapeutic option to improve prognosis for lung cancer patients. First clinical trials with therapies targeting the programmed cell death receptor PD-1 and its ligand PD-L1 have shown promising results in several solid tumors. However, in lung cancer t...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:PLoS One
Egile Nagusiak: Schmidt, Lars Henning, Kümmel, Andreas, Görlich, Dennis, Mohr, Michael, Bröckling, Sebastian, Mikesch, Jan Henrik, Grünewald, Inga, Marra, Alessandro, Schultheis, Anne M., Wardelmann, Eva, Müller-Tidow, Carsten, Spieker, Tilmann, Schliemann, Christoph, Berdel, Wolfgang E., Wiewrodt, Rainer, Hartmann, Wolfgang
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Public Library of Science 2015
Gaiak:
Research Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4552388/
https://ncbi.nlm.nih.gov/pubmed/26313362
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0136023
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak